Good morning. It is Monday, September 14, 2026, and the cannabis sector opens the week carrying significant regulatory and corporate momentum. Curaleaf Holdings (CURLF) broke overnight with a direct legal escalation against Aurora Cannabis (ACB) at the Alberta Securities Commission, the DEA Schedule III rescheduling window continues to tighten toward an October inflection, and the broader MSO universe enters a week defined by earnings setup and state-level regulatory catalysts. Here is your morning market intelligence from Sheeba.
Breaking: Curaleaf Files at Alberta Securities Commission to Halt Aurora ATM Dilution
Curaleaf Holdings submitted an emergency application this morning to the Alberta Securities Commission (ASC) seeking to stop Aurora Cannabis from continuing share issuances under its at-the-market program while Curaleaf’s acquisition offer remains outstanding. Curaleaf has requested an expedited hearing.
Aurora established its ATM program in February 2026, publicly stating proceeds would be used for “strategic and accretive purposes only.” Aurora simultaneously describes itself as holding approximately C49 million in cash and carrying no debt. Curaleaf’s position is that continuing to issue shares below the offer price while sitting on a fortress balance sheet is solely a defensive management tactic designed to dilute shareholders and raise the cost of the offer.
By the numbers, Aurora’s ATM issuances have diluted Aurora shareholders by approximately 11% since the program launched, and by roughly 5% since June 2026. The dilution has also increased the cost of Curaleaf’s offer by more than US1 million. Curaleaf’s .00 per share offer represents a premium to Aurora’s pre-announcement trading levels.
Curaleaf CEO Boris Jordan said: “Every share Aurora sells below the Offer price raises the same question: if management believes US.00 undervalues the company and the company has ample cash, why continue diluting its shareholders?”
For CURLF holders, the ASC filing is a direct escalation signal. If the commission grants an expedited halt order, the overhang from ongoing ATM dilution is removed and Curaleaf’s path to reaching offer acceptance thresholds becomes materially cleaner. Track Curaleaf on the weedstock tracker.
DEA Schedule III Window: October Countdown Tightens
The DEA Schedule III final rule timeline remains the dominant macro variable for the entire cannabis sector. The administrative law judge process has completed its final briefs phase as of early September. Market participants are increasingly focused on the October window as the inflection point where a final rule could be published, or the timeline slips to Q1 2027.
Schedule III reclassification removes the Section 280E federal tax treatment that currently forces cannabis companies to pay effective tax rates exceeding 60% of adjusted gross income on state-legal operations. For operators like Green Thumb Industries (GTBIF), Trulieve (TCNNF), and Curaleaf (CURLF), 280E relief alone would represent a step-function change in net income and free cash flow without any change in revenue.
Green Thumb Industries reported Q2 2026 revenue of 07 million, up 5% year over year, with normalized EBITDA of 4 million and strong operating cash flow. GTI continued share repurchases and disciplined CapEx allocation through the quarter, while highlighting regulatory progress in Virginia and Texas as near-term organic growth drivers. Track Green Thumb on the weedstock tracker.
State Regulatory Calendar: Pennsylvania and New Hampshire Lead the Week
Pennsylvania’s adult-use licensing framework continues its rollout, with the state cannabis control board expected to release additional application guidance this week. Pennsylvania represents one of the most significant near-term market expansion opportunities for established MSOs with existing medical dispensary infrastructure, notably Trulieve, Curaleaf, and Cresco Labs (CRLBF).
New Hampshire’s adult-use program, which entered the regulatory buildout phase earlier this summer, continues to represent a smaller but symbolically important Northeast market. For operators with New England density, New Hampshire is an incremental license-to-revenue story in 2027.
MSO Sector Setup: Earnings Season Approaches as October Catalyst Looms
Several operators report Q3 2026 results in the coming weeks. The narrative entering earnings season is defined by two variables: whether 280E relief materializes in October, and whether operators are generating enough organic free cash flow to execute buybacks and deleveraging without the regulatory tailwind.
Verano Holdings (VRNOF) has been building on its Illinois and multi-state retail density story through the summer. Cresco Labs (CRLBF) continues to benefit from Illinois wholesale strength and Pennsylvania retail momentum. Both names enter this week with the Curaleaf-Aurora ASC development providing an additional sector attention catalyst.
Glass House Brands (GLASF) faces a different variable set: California adult-use demand trajectory and wholesale price dynamics rather than rescheduling-driven earnings uplift. Watch GLASF as a beta play on California market normalization. Track the full sector on the weedstock tracker.
Morning Positioning Notes from Sheeba
The Curaleaf ASC filing is the single most actionable development this morning. An expedited ruling removing the ATM dilution overhang could sharpen near-term price discovery around the .00 offer floor. For the broader sector, the DEA October window means the next six weeks are the highest-stakes regulatory period of 2026. Weedstock will track all developments through the trading day.
— Sheeba, Weedstock Market Intelligence | September 14, 2026